FDA and NCI Officials to Address Tobacco Law, Research at AACR Briefing
March 14, 2011
WASHINGTON, D.C. — In 2009, a historic new law granted the U.S. Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing and sale of tobacco products. The FDA will give an update on the implementation of the Family Smoking Prevention and Tobacco Control Act at a congressional briefing hosted by the American Association for Cancer Research on Wednesday, March 16.
Lawrence Deyton, M.D., M.S.P.H., director of the FDA Center for Tobacco Products, will discuss the FDA’s progress and plans toward full realization of the law. Deyton has served as director of the center since August 2009.
The briefing will be held from 12 to 1:30 p.m. ET on March 16 in room HVC-200 of the Capitol Visitor Center. Media are invited to attend; visit www.aacr.org/FDAbriefing for more information. Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR, will moderate the briefing.
“The passage of the Family Smoking Prevention and Tobacco Control Act was an important and needed step toward curbing the tobacco epidemic in America,” Foti said. “The AACR will do everything it can to build the scientific evidence to support the FDA in regulating a product that causes so much harm.”
Leading the discussion at the briefing on federal efforts to address the FDA’s research needs will be Robert T. Croyle, Ph.D., director of the division of cancer control and population sciences at the National Cancer Institute (NCI). Roy S. Herbst, M.D., Ph.D., chair of the AACR’s Task Force on Tobacco and chief of medical oncology at Yale University, will address the role of organizations like the AACR in helping the FDA and NCI achieve their goals. In April 2010, the AACR Task Force facilitated the development of an AACR policy statement on tobacco and cancer.
Rep. Todd Platts, R-Pa., is co-hosting the briefing, along with Rep. Rosa DeLauro, D-Conn., and Sen. Frank Lautenberg, D-N.J. All three were co-sponsors of the Family Smoking Prevention and Tobacco Control Act. Platts will provide opening remarks for the event.
This briefing is the second AACR-led one in March on the topic of tobacco, which is responsible for nearly 30 percent of all cancer deaths, taking the lives of 169,000 Americans every year. An AACR briefing on March 1 featured U.S. Surgeon General Regina Benjamin, who spoke about her recent report on how tobacco smoke causes disease.
# # #
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: /PressRegistration
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.